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Abstract:  Cerebellar  ataxias  are  a  group  of  disabling  neurological  disorders.  Patients  exhibit  a  cerebellar  syndrome  
and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, 
pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. 
Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the pheno-
typic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in 
particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neuro-
transmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal 
models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development 
of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we 
discuss the drugs under development. 
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I. INTRODUCTION 
  With the advent of sensitive techniques such as magnetic 
resonance imaging (MRI), cerebellar ataxias (CAs) are being 
growingly recognized [11, 36, 57, 145, 165, 224]. There is a 
medical need to develop effective therapies in this group of 
disabling disorders for which no cure is currently available. 
For the first time, novel therapeutics aiming to target delete-
rious pathways are under development [100, 135, 214, 219]. 
The  deciphering  of  the  molecular  mechanisms  underlying 
CAs is a preliminary and unavoidable step to reach the goal 
of the cure [135]. Major advances in our current understand-
ing of the pathogenesis of cerebellar ataxias have originated 
in particular from the development of relevant animal mod-
els which mimic the phenotype observed in human [90, 135, 
166, 167, 173, 185]. Advances in brain neuroimaging have 
also improved drastically the early detection and follow-up 
of the course of cerebellar disorders [51, 77, 113]. This paper 
reviews the most common causes of CAs, the therapies used 
in the past and the treatments under assessment both at the 
experimental  and clinical level. The main cerebellar disor-
ders will be briefly presented for a matter of clarity. 
II. CEREBELLAR ATAXIAS: DESCRIPTION 
  CAs can affect the medial zone (vermal zone), the inter-
mediate zone (paravermal  zone) and/or  the  lateral zone of  
the  cerebellum  [133].  The  main  symptoms  are  listed  in  
Table  1.  Cerebellar  patients  are  typically  clumsy  during  
voluntary movements involving proximal or distal joints [64, 
84,  209].  Cerebellum  is  also  involved  in  several  forms  
of motor learning [121, 125, 207]. CAs are a heterogeneous  
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group of disabling disorders characterized by a lack of coor-
dination and imbalance [114]. Patients exhibit various com-
binations of oculomotor deficits, dysarthria, dysmetria and 
kinetic tremor [138, 220]. Recently, the association of cere-
bellar lesions and neuropsychiatric symptoms has been un-
derlined (Table 2). It has been suggested that the cerebellum 
is involved in the pathogenesis of depression, schizophrenia 
and autism [58]. For instance, autism is associated with de-
creased densities of Purkinje neurons [124, 175, 228]. Some 
ataxic  diseases  present  with  marked  cognitive  dysfunction 
[181]. A typical example is SCA17, a highly heterogeneous 
disease with cognitive impairment in 80 to 100 % of cases 
[17, 65, 132, 239]. CAs can be divided in sporadic and inher-
ited disorders [135]. Table 3 lists the principal disorders in-
volving the cerebellum in young adults and for whom phar-
macological  treatments  have  been  or  are  being  evaluated 
[135]. 
II.1.  Cerebellar  Circuitry:  Composition,  Neurotrans- 
mitters and Receptors 
  Cerebellum is the region of the brain containing the high-
est number of neurons [132]. Cerebellar circuitry is highly 
complex. The cerebellum is composed of a mantle of grey 
zone (cortex) surrounding white matter, in which cerebellar 
nuclei are disposed [49]. Despite an apparent homogeneous 
structure, cerebellum is divided into several functional zones 
[208].  Three  rostro-caudal  longitudinal  zones  have  been 
identified in the cerebellar cortex: a vermal zone projecting 
to the fastigial nucleus medially, an intermediate zone pro-
jecting to the interpositus nucleus and a lateral zone project-
ing  to  the  dentate  nucleus  [73].  Two  categories  of  inputs 
reach cerebellar cortex: mossy fibers issued from brainstem 
nuclei and climbing fibers originating from the inferior oli-
vary complex [86]. Cerebellar cortex is composed of Purk-
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Purkinje neurons exert an inhibitory effect upon cerebellar 
nuclei,  which  represent  the  sole  output  of  cerebellar  cir-
cuitry. There is increasing evidence of a functional asymme-
try of the cerebellum, not only for motor but also for higher 
cognitive  functions  and  sensory  discrimination  regarding 
processes  like  pain  [18,  26,  85,  196,  232].  Another  major 
feature of the cerebellar circuitry is the rostrocaudal and me-
diolateral subdivision of the cerebellar cortex into complex 
arrays of transverse zones and parasagittal stripes [3, 35, 82]. 
The  most  extensively  studied  marker  for  cerebellar  com-
partmentation is the antigen zebrin II, an epitope on the res-
piratory isoenzyme aldolase C [156]. Zebrin II is expressed 
by a subset of Purkinje neurons forming parasagittal stripes 
which are highly reproducible between subjects and across 
species [156]. The molecular mechanisms which govern the 
distribution  and organization of cerebellar zones are being 
unraveled and will probably lead to novel therapies [192].  
  Table 4 lists the neurotransmitters and neuromodulators 
of cerebellar circuitry. Distribution of the main receptors is 
illustrated in Fig. (1). Glutamate is a transmitter for both the 
mossy fiber and the climbing fiber system [191]. The post-
synaptic  element  of  the  synapse  mossy  fiber-granule  cell 
presents  N-methyl-D-aspartate  (NMDA)  and  aminohy-
droxymethylisoxazoleproprionate  (AMPA)  receptors  [199]. 
Some mossy fibers contain choline acetyl transferase and use 
acetylcholine (Ach) as transmitter [110]. Climbing fibers are 
enriched in glutamate and can retrogradely transport aspar-
tate to the inferior olive [94]. Glutamate is also the transmit-
ter of parallel fibers which  make numerous  synapses with 
dendritic spines. Purkinje cell spines contain high densities 
of AMPA receptors [230]. Purkinje cells are enriched in glu-
tamic acid decarboxylase (GAD), a GABA synthesizing en-
zyme [16]. Both ionotropic GABA receptors (GABA-A) and 
metabotropic  GABA  receptors  (GABA-B)  are  highly  ex-
pressed  in the cerebellum. GABA-B receptors  are particu-
larly enriched in the cerebellar cortex [118, 137, 218]. At the 
cellular  level,  the  GABA-B1  and  GABA-B2  subunits  are 
distributed in most neurons of the adult cerebellar cortex, but 
in particular at high levels in Purkinje neurons [105, 130]. 
  Taurine is also enriched in Purkinje cells and is consid-
ered to play a role  in osmoregulation [88]. Recent studies 
have demonstrated that retrograde messengers, the endocan-
nabinoids, are released by Purkinje cells [179]. Type 1 can-
nabinoid receptors (CB1Rs) are expressed presynaptically at 
all  synaptic  inputs  to  the  Purkinje  neurons  [206].  A  high 
proportion of CB1Rs are also located at inhibitory interneu-
rons  throughout  the  molecular  layer.  Labelling  studies  are 
consistent with their presence in basket cell and stellate cell 
inhibitory interneurons [48].  
Table 2.   Neuropsychiatric Symptoms in Cerebellar Disorders 
Domain  Symptoms 
Attention  Distractibility 
Hyperactivity 
Compulsive behaviour 
Perseveration 
Difficulties for shifting attention 
Obsessional behavior 
Emotion  Impulsiveness, disinhibition 
Anxiety, agitation 
Pathological laughing and crying 
Anhedonia 
Depression 
Dysphoria 
Social skill set  Aggression 
Irritability 
Passivity 
Difficulties with social interactions 
Psychosis  Illogical thinking 
Hallucinations 
Lack of empathy 
Autism spectrum  Stereotypies 
Avoidant behavior 
Sensory overload 
Adapted from Schmahmann and Pandya (2008) [182]. 
  GABA  is  the  predominant  transmitter  of  cerebellar  in-
terneurons  (basket  cells,  stellate  cells,  Golgi  cells,  Lugaro 
cells). Glycine is also supposed to be involved in the inhibi-
Table 1.   Main Clinical Deficits in Cerebellar Patients 
Vermal Zone  Paravermal Zone  Lateral Zone 
Oculomotor deficits 
Dysarthria 
Head tilt 
Ataxia of stance/gait 
Dysarthria  Oculomotor deficits 
Dysarthria 
Dysmetria 
Kinetic tremor 
Hypotonia 
Dysdiadochokinesia 
Decomposition of movements 
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tory  processes  controlled  by  cerebellar  interneurons  [19]. 
The unipolar brush cells are an exception in the population 
of interneurons, since they are glutamatergic. 
Table 3.   Differential  Diagnosis  of  Cerebellar  Ataxias  in 
Young Adults 
Spinocerebellar ataxia (SCA) 
Episodic ataxia (EA) 
Friedreich ataxia (FRDA)  
Wilson disease 
Primary tumor 
Paraneoplastic ataxia 
Infectious/para-infectious 
Immune ataxia 
Toxics (alcohol) 
Endocrine diseases 
Leukodystrophies 
Mitochondrial disorders 
Table 4.   Main  Neurotransmitters  and  Neuromodulators  of 
Cerebellar Circuitry 
Glutamate 
Aspartate 
GABA 
Glycine 
Taurine 
Amines (Serotonin, Noradrenaline, Acetylcholine, Dopamine, Hista-
mine) 
Nitric oxide 
Peptides 
Endocannabinoids 
 
  Aminergic fibers are found in the 3 layers of the cerebel-
lar cortex (Table 5). Serotoninergic fibers are distributed in 
all parts of the cerebellum, except lobule X [227]. Serotonin 
inhibits glutamate release from mossy fibers, tunes cellular 
responses to GABA and regulates the activity of glial GABA 
transporters [189]. Local application of serotonin modulates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Representation of the connectivity of cerebellar neurons and expression of receptors. Two categories of inputs  reach the  
cerebellar cortex: (1) the mossy fibers targeting granule cells and cerebellar nuclei (DCN), and (2) the climbing fibers originating from the 
inferior olivary complex (IO) and projecting to cerebellar nuclei and Purkinje neurons. Granule cells give rise to parallel fibers which make 
numerous synapses with dendritic spines of Purkinje cells. Inhibitory interneurons of the cerebellar cortex include basket cells, stellate cells 
and  Golgi  cells.  Abbreviations:  AMPA:  aminohydroxymethylisoxazoleproprionate,  NMDA:  N-methyl-D-aspartate,  mGluR.  GABAA: 
GABA-A receptor, GABAB: GABA-B receptor, 5-HT: serotonin, CB1: cannabinoid 1 receptor. 44    Current Neuropharmacology, 2010, Vol. 8, No. 1  Marmolino and Manto 
the  firing  rate  of  Purkinje  cells  both  in  vivo  and  in  vitro. 
Lugaro  cells  are  also  responsive  to  serotonin  [226].  The 
noradrenergic  input  modulates  the  responses  of  cerebellar 
neurons  to  GABA  and  glutamate.  Interestingly,  a  genuine 
dopaminergic  innervation  is  also  found  in  the  cerebellum 
[189]. Dopamine and dopamine transporters are found in all 
the layers of the cerebellar cortex, with the highest densities 
in the molecular layer [44, 162]. Dopamine immunoreactive 
axons are found in the cerebellar vermis of primates, primar-
ily innervating the granule cell layer and the adjacent Purk-
inje  neurons  [89,  146].  Biochemical  investigations  have 
shown active dopamine uptake into cerebellar synaptosomes 
and release of endogeneous dopamine by the cerebellum [55, 
70].  Radioligand  binding  studies  have  demonstrated  that 
dopamine  receptors  1-5,  which  belong  to  the  D1-like  and 
D2-like superfamilies, are expressed in the cerebellum [28, 
45]. D1 and D5 receptors are localized in Purkinje neurons 
and the molecular layer, D2 receptors are found in all layers, 
D3 receptors are principally found in Purkinje neurons and 
molecular layer of lobules IX and X, and D4 receptors are 
concentrated in the molecular layer [70]. Levels of dopamine 
transporters (DAT) binding are a good indicator of the ex-
tracellular dopamine content. DAT bindings change in paral-
lel  to  the  concentrations  of  dopamine  in  the  extra-cellular 
space [161]. DAT knockout mice (DAT -/-) are hyperactive 
[237].  Extra-cellular  dopamine  levels  are  increased  in  the 
striatum, causing a depression in mRNA levels of both D1 
and D2 receptors and decreased stores of dopamine [71, 96]. 
Interestingly, several lines of evidence suggest that cerebel-
lar  dopaminergic  system  is  a  potential  target  of  drugs  of 
abuse [70]. Systemic administration of d-amphetamine and 
cocaine causes a dose-response increase in c-fos expression 
in the rat cerebellum, an effect which is reduced by pretreat-
ment  with  SCH23390,  a  D1  receptor  antagonist  [59]. 
Moreover, a chronic treatment with cocaine sensitizes c-fos 
induction in the cerebellum via D1 and D2 receptors, and d-
amphetamine increases the density of D2-like receptors [27, 
39,  111].  Studies  with  cerebellar  membrane  preparations 
have shown that the [3H]GBR12935 specific binding is sen-
sitive to mazindol, a specific dopamine transporter antago-
nist, and dopamine. Mazindol inhibits 15-20 % of the total 
specific binding with high affinity and the remaining 80-85 
% with low affinity [44]. A complementary inhibitory pat-
tern is observed with cis-flupentixol. Saturation experiments 
in presence of cis-flupentixol have revealed a specific bind-
ing site with a Kd value similar to the value in striatal prepa-
rations.  Nevertheless,  the  affinity  of  dopamine  for  the 
[3H]GBR12935 specific binding is lower in the cerebellum, 
suggesting  different  three-dimensional  conformations  and 
ligand binding properties.  
  The hypothalamus projects to the cerebellum using his-
tamine as transmitter [50]. Histaminergic fibers are found in 
all cortical layers of the cerebellum. H1 receptors are prefer-
entially expressed on Purkinje cell dendrites [213]. 
  Activation of NMDA receptors in the cerebellum stimu-
lates the production of nitric oxide (NO) [60]. Granule cells 
are a main source of NO [131]. Granule cells, parallel fibers 
and basket cells are equipped with the neuronal isoform of 
NO synthase (nNOS). Release of NO from parallel fibers is 
involved in long-term depression (LTD) [157]. Production of 
cyclic guanosine monophosphate (cGMP) results indirectly 
from NO production [76]. cGMP immunoreactivity is found 
mainly in Bergmann glia and astrocytes [198].  
Table 5.   Sites  of  Projections  of  Aminergic  Pathways  in  the 
Cerebellum 
Amine  Site of Projection in the Cerebellum 
Serotonin  Cerebellar cortex: dense plexus in granular and 
Purkinje cell layer 
Cerebellar nuclei: dense plexus 
Noradrenaline  Cerebellar cortex: around glomeruli and around 
dendrites of Purkinje cells  
Cerebellar nuclei 
Acetylcholine  Cerebellar cortex  
Cerebellar nuclei 
Dopamine  Cerebellar cortex 
Histamine  Cerebellar cortex 
 
II.2. Inherited CAs 
  The  inherited  ataxias  are  related  to  a  genetic  deficit  
(Table 6). They can be divided into four groups: autosomal 
dominant ataxias, autosomal recessive ataxias, mitochondrial 
ataxias and X-linked ataxias [14, 112, 115, 135, 159].  
II.2.1. Autosomal Dominant Ataxias (ADCAs) 
  Onset varies from infancy to the elderly. In most cases, 
symptoms start between the ages of 20 and 60 [135].  
Spinocerebellar Ataxias (SCAs) 
  SCAs are a set of genetic and clinically heterogeneous 
diseases which share the feature of progressive ataxia [135, 
184].  They  have  an  incidence  of  1  to  4  affected  every 
100.000 [215]. SCAs are classified genetically according to a 
specific  mutation  or  mapped  locus,  and  also  according  to 
clinical  findings  [207].  Dentatorubropallidoluysian  atrophy 
(DRPLA) and ataxia associated with fibroblast growth factor 
14  (FGF14)  mutation  are  also  considered  in  this  group  
[136]. 
  The majority of known mutations involve a sequence of 
CAG trinucleotide repeats within the coding tract in the re-
spective  gene.  This  is  the  case  for  SCA1,  SCA2,  SCA3, 
SCA6, SCA7, SCA17, and DRPLA, while a CTG repeats is 
present in SCA8 [207]. Trinucleotide repeats are associated 
with an abnormal polyglutamine accumulation and formation 
of nuclear aggregates [155]. A pentanucleotide repeat expan-
sion  ATTCT  is  associated  with  SCA10  [142].  SCA5, 
SCA13,  SCA14,  and  16q22-linked  autosomal  dominant 
cerebellar ataxia (ADCA) are characterized by point muta-
tions [108, 147, 158, 229]. Patients exhibit various combina-
tions of cerebellar and extra-cerebellar deficits (Table 7). 
II.2.2. Episodic Ataxias (EAs) 
  EAs  are  a  group  of  diseases  underlying  a  monogenic  
mutation (EA 1-7; Table 8) [102]. The onset of symptoms is Therapies of Cerebellar Ataxias  Current Neuropharmacology, 2010, Vol. 8, No. 1    45 
Table 6.   Gene Mutations in Inherited Ataxias 
Autosomal Dominant Spinocerebellar Ataxias 
Type  Gene Mutation  Protein 
SCA1  CAG (35-83)  Ataxin-1 
SCA2  CAG (34-750)  Ataxin-2 
SCA3  CAG (56-86)  Ataxin-3 (MJD1) 
SCA4  -  - 
SCA5  Missense mutations  Spectrin 
SCA6  CAG (19-33)  Calcium channel, voltage-dependent,  
P/Q, α-A subinit 
SCA7  CAG (41-306)  Ataxin-7 
SCA8  CTG (80-300)  Ataxin-8 
SCA10  ATTCT (800-4500)  Ataxin-10 
SCA11  TTBK2 (1329insA, 1284_1285delAG)  Tau Tubulin kinase-2 
SCA12  CAG (66-93)  Protein phosphatase 2, regulatory subunit  
B, β-isoform 
SCA13  KCNC3 (R420H, F448L)  Voltage-gated potassium channels, shaw-related 
subfamily, member 3 
SCA14  Missense mutations  Protein kinase C, g-polypeptide 
SCA15  ITPR1 (DEL EX1-48, P1059L)  Type 1 inositol 1, 4, 5-triphosphate receptor 
SCA16  -  - 
SCA17  CAG/CAA (43-63)  TATA box-binding protein 
SCA18  -  - 
SCA19  -  - 
SCA20  -  - 
SCA21  -  - 
SCA22  -  - 
SCA24  -  - 
SCA25  -  - 
DRPLA  CAG (48-93)  Atrophin-1 
SCA27  FGF 14  Fibroblast growth factors 
SCA31  PLEKHG4 (16C-T)  Puratrophin-1 
FRDA  9q13  Frataxin 
Familial coenzyme Q10(CoQ10) deficiency  CoQ10  CoQ10 
Autosomal-recessive spastic ataxia of  
Charlevoix-Saguenay (ARSACS) 
13q12  Sacsin 
Mitochondrial recessive ataxic syndrome 
(MIRAS) 
  Polymerase−γ 
Marinesco-Sjögren syndrome  5q32  SILI 
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Table 6. cont…. 
Autosomal Dominant Spinocerebellar Ataxias 
Type  Gene Mutation  Protein 
Ataxia with isolated vitamin E deficiency 
(AVED) 
8q13  Alpha-tocopherol transfer protein (α-TTP) 
Abetalipoptoteinemia 
(Bassen-Kornzweig syndrome) 
4q22-q24  Microsomal triglyceride transfer protein 
Hereditary motor and sensory neuropathy  
type IV (HMSM IV),  
Refsum disease 
10pter-p11.2  Phytanoyl-CoA hydroxylase 
Cerebrotendinous xanthomatosis  2q33-qter  Cytocrome P-450, subfamily VVVIIA,  
polypeptide 1 (sterol 27-hydroxylase) 
Metachromatic leucodystrophy  22q13  Arylsulfatase 1 
Niemann-Pick type C  18q11-121  NPC1 protein 
GM2-gangliosidosis (Tay-Sachs disease)  15q23-24  Hexosaminidase 1 
Chorea-acanthocytosis  9q21  Chorein 
Wilson’s disease  13q14-21  ATPase Cu transporting beta-polypeptide 
Aceruloplasminaemia  3q23-q24  Ceruloplasmin 
Ataxia telangiectasia  11q22.3  ATM 
Ataxia-telangiectasia-like disorder (ATLD)  11q21  MREIIA 
Ataxia with oculomotor apraxia 1 
(AOA1/EAOH) 
9p13  Aprataxin 
Ataxia with oculomotor apraxia 2 (AOA2)  9q34  Senataxin 
 
generally  in  the  childhood  [100].  Anxiety  and  fatigue  in-
crease the susceptibility to an attack [30]. EA-2 is the most 
common  episodic  ataxia  [34].  Patients  may  exhibit  myo-
kymia, nystagmus, vertigo, and ataxia [101, 169]. EA-1 is 
characterized  by  short  attacks  of  incoordination  and 
dysarthria (slurred speech).  
II.2.3. Autosomal Recessive Ataxias (ARCAs) 
  ARCAs are disorders characterized by variable combina-
tions of central and peripheral nervous system involvement 
[57].  Dysfunctions  of  other  organs  are  found  in  some  
ARCAs  [220].  The  most  common  ARCA  is  Friedreich’s 
ataxia  (FRDA).  Other  recessive  ataxias  include  ataxia-
telangiectasia,  ataxia  with  ocular  motor  apraxia  (AOA), 
ataxia  with  vitamin  E  deficiency  (AVED),  ataxia  with 
CoQ10  deficiency,  abetalipoproteinemia,  early-onset  cere-
bellar  ataxia  with  retained  tendon  reflexes,  infantile  onset 
spinocerebellar  ataxia,  Marinesco-Sjogren  syndrome  and 
spastic ataxia of Charlevoix-Saguenay [30, 135]. There are 
numerous  additional  types  of  recessive  ataxias  worldwide, 
identified in a few families only. The most common ARCAs 
are briefly described below. 
  Friedreich’s  ataxia  (FRDA)  is  due  to  a  pathological 
GAA  triplet  expansion  within  the  first  intron  of  the  FXN 
gene,  codifying for  the mitochondrial protein frataxin [32, 
140]. It is a severe neurodegenerative disorder, with an inci-
dence of 1/40.000 [43]. The clinical picture is characterized 
by gait and limb ataxia, dysarthria, areflexia, proprioceptive 
loss and Babinski sign [62]. Patients can also develop car-
diomyopathy and diabetes mellitus [62]. There is a consen-
sus that FRDA is a disorder of iron homeostasis at the mito-
chondrial level [66, 115]. 
  Cerebellar ataxia with muscle Coenzyme Q10 deficiency 
is  a  heterogeneous  disorder.  The  cerebellar  form  presents 
with  ataxia  and  cerebellar  atrophy  [148,  150,  122].  Coen-
zyme Q10 (CoQ10; ubiquinone), is an electron carrier criti-
cal for electron transfer within the mitochondrial respiratory 
chain (see section IV.2). 
  Ataxia with Vitamin E deficiency (AVED), presents as 
a  FRDA-like  syndrome  [6,  20].  The  744deletionA  is  the 
most  common  mutation.  Abetalipoproteinaemia  (ABL)  is 
characterized by a deficit in the low density apolipoprotein-B 
(VLDLs). Symptoms are similar to AVED. 
  Ataxia-telangiectasia  is  the  most  frequent  ARCA  in 
children [67, 68]. First symptoms usually begin between 2-8 
years. A mutation within the ATM gene results in a deficit in 
the DNA repair [193].  
  Ataxia with oculomotor apraxia (AOA) type 1 is due to 
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poalbuminemia [41, 42]. AOA type 2 is due to a mutation in 
the senataxin gene [10]. AoA2 is associated with increased 
alpha-fetoprotein levels in blood [123]. 
  Late-onset  Tay-Sachs  disease  (LOTSD)  is  character-
ized by a deficiency in beta-hexosaminidase due to a muta-
tion in the HEXA gene [149]. Patients presents a FRDA-like 
phenotype. 
  Cerebrotendinous xanthomatosis (CTX) patients carry 
a  mutation  within  the  mitochondrial  enzyme  sterol  27-
hydroxylase (CYP27). Serum analysis shows increased lev-
Table 7.  Clinical Presentations of Spinocerebellar Ataxias 
Pure cerebellar syndrome  SCA5, SCA6, SCA11, SCA26 
Cerebellar ataxia plus:   
Cognitive impairment/ behavioural symptoms  SCA1, SCA2, SCA3, SCA10, SCA12, SCA13, SCA14, SCA17, SCA19, SCA21, SCA-FGF14, DRPLA 
Seizures  SCA10, SCA17, DRPLA 
Eyes/oculomotor deficits   
Slow saccades  SCA1, SCA2, SCA3, SCA7, SCA28 
Down-beat nystagmus  SCA6 
Ophthalmoparesia  SCA1, SCA2, SCA3, SCA28, SCA30 
Ocular dyskinesia  SCA10 
Pigmentary retinopathy  SCA7 
Movement disorders   
Parkinsonism  SCA1, SCA2, SCA3, SCA12, SCA17, SCA21 
Dystonia  SCA3, SCA14, SCA17 
Tremor  SCA8, SCA12, SCA16, SCA19, SCA20 
Dyskinesias  SCA-FGF14 
Myoclonus  SCA2, SCA14, SCA19, DRPLA 
Chorea  SCA1, SCA17, DRPLA 
Myokymia  SCA5 
Pyramidal signs  SCA1, SCA2, SCA3, SCA4, SCA7, SCA8, SCA10, SCA11, SCA12, SCA13, SCA14, SCA15, SCA28, 
SCA30 
Peripheral neuropathy  SCA1, SCA2, SCA3, SCA4, SCA6, SCA8, SCA-FGF14, SCA12, SCA18, SCA22, SCA25 
 
Table 8.  Genetics of Episodic Ataxias (EAs) 
Type of Ataxia  Gene Mutation and Function 
Type 1 (EA-1)  KCNA1-deficiency in voltage-gated potassium channel function 
Autosomal dominant 
Type 2 (EA2)  CACNA1A-subunit of P/Q type calcium channel; different mutations in same gene lead to SCA6 and familial hemiplegic migraine 
CACNB4-dihydropyridine-sensitive L-type calcium channel 
Autosomal dominant 
Type 3 (EA-3)  Linked to 1q42 
Type 4 (EA-4)  Unknown 
Type 6 (EA-6)  Unknown 
Type 7 (EA-7)  19q13 
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els of cholestanol and bile  alcohols [202]. Patients  exhibit 
combinations of dementia, psychiatric disturbances, pyrami-
dal  deficits,  extra-pyramidal  deficits  (dystonia),  cerebellar 
signs, seizures, and peripheral neuropathy [192]. Neuropsy-
chiatric symptoms such as hallucinations, agitation, depres-
sion, and suicide attempts may be prominent. Infantile-onset 
diarrhea,  cataract  and  tendon  xanthomas  are  suggestive 
[223]. 
  Refsum’s disease is caused by mutation of the gene for 
the  peroxisomal  enzyme  phytanoyl-CoA  hydroxylase, 
PHYH [99]. The age of onset varies from early childhood to 
50 years of age. Most patients have symptoms before age of 
20 years. The main clinical features are retinitis pigmentosa, 
chronic polyneuropathy, and cerebellar ataxia [109]. Anos-
mia, sensorineural deafness, cardiac arrhythmias, renal fail-
ure, bony and skin abnormalities have been reported [126].  
  SCA with axonal neuropathy (SCAN1) is due to a mu-
tation within the TDP1 gene, encoding for the tyrosyl-DNA 
phosphodiesterase  1  [56].  SCAN1  is  characterized  by  pe-
ripheral  sensori-motor  axonal  neuropathy,  distal  muscular 
atrophy, and pes cavus. Patients exhibit steppage during gait. 
The  phenotype  can  mimick  Charcot-Marie-Tooth  disease. 
Patients have a history of seizures. 
  The recessive spinocerebellar ataxia type 1 (SCAR8; 
ARCA1) maps to locus 6q25. The disease is caused by mu-
tations in the SYNE1 gene [54]. SCAR8 was initially identi-
fied in French Canadian families originating mainly from the 
Beauce and Bas-St-Laurent regions of the province of Que-
bec (Canada). Patients present a late-onset cerebellar ataxia 
with  slow  progression  [74].  They  exhibit  dysarthria,  dys-
metria, occasional brisk lower-extremity tendon reflexes, and 
minor oculomotor abnormalities. Brain MRI shows a diffuse 
pure cerebellar atrophy.  
  Autosomal  recessive  spastic  ataxia  of  Charlevoix-
Saguenay (ARSACS) is due to a deficit in the chaperone 
protein sacsin (SACS) [222]. The age of onset ranges from 1 
to 14 years [29]. ARSACS is  characterized by early-onset 
spastic  ataxia,  axonal  and  demyelinating  neuropathy,  and 
hypermyelination of retinal nerve fibers [205]. Pes cavus is 
common.  Gait  unsteadiness  is  the  first  symptom  in  most 
cases. A minority of patients develop seizures. Intelligence is 
usually normal.  
  In the infantile-onset spinocerebellar ataxia (IOSCA) 
the gene C10orf2 encoding for the protein twinkle, a mito-
chondrial helicase involved in DNA replication, is mutated 
[154]. The disease has been described in Finland and is char-
acterized  by  a  very  early  onset  ataxia  (between  1  and  2 
years), athetosis and tendon hyporeflexia. Ophthalmoplegia, 
hearing loss, and sensory neuropathy appear later in the dis-
ease  course.  Refractory  status  epilepticus,  migraine-like 
headaches and severe psychiatric symptoms are also sugges-
tive [128].  
  Marinesco-Sjögren syndrome (MSS) is due to a muta-
tion in the chaperone protein HSPA5 transcribed by the gene 
SIL1  [5].  Symptoms  of  MSS  start  in  the  infancy  [221]. 
Manifestations  include  cerebellar  ataxia,  congenital  cata-
racts,  retarded  somatic  and  mental  development,  muscle 
weakness, hypotonia and tendon areflexia.  
  Wilson disease, a treatable disorder resulting from cop-
per  accumulation  and  subsequent  hepatic  dysfunction,  has 
variable presentations. Cerebellar symptoms may be present 
and tremor appears in up to 50% of patients. The Kayser-
Fleischer ring (a deep copper-colored ring at the periphery of 
the cornea, the color ranging from greenish gold to brown) is 
observed in up to 90% of individuals and is almost invaria-
bly present in patients with neurologic manifestations. Low 
ceruloplasmin levels are found in blood. Levels of total cop-
per  are  decreased.  Hemolytic  anemia  (Coombs-negative) 
occurs in 10-15 % of cases. 
II.2.4. Mitochondrial Disorders 
  This  group  gathers  diseases  due  to  mutations  in  mito-
chondrial genes. Most genes are involved in the energy pro-
duction,  essentially  in  oxidative  phosphorylation  [238]. 
Some mitochondrial disorders have ataxia as a main symp-
tom,  such  as  Kearns-Sayre  Syndrome,  May-White  Syn-
drome,  MNGIE  (ophthalmoparesia,  peripheral  neuropathy, 
and  gastrointestinal  symptoms),  Leigh  syndrome,  NARP 
(neuropathy, ataxia, and retinitis pigmentosa), MELAS (mi-
tochondrial encephalomyopathy, lactic acidosis with stroke-
like  episodes),  and  MEERF  (myoclonus  epilepsy  with 
ragged red fibers) [63]. Mutations within the mitochondrial 
DNA polymerase (POLG) catalytic subunit γ are associated 
with a progressive external ophthalmoplegia and hepatocere-
bral disturbances [33].  
II.2.5. X-linked Inherited Ataxias 
  The commonest X-linked  ataxias are listed  in Table 9. 
Fragile-X tremor ataxia syndrome (FXTAS) is rare disease 
in which a CGG mutation is carried on the X chromosome 
[97, 98]. The disorder usually starts after 50 years. Typical 
symptoms  are  gait  ataxia,  kinetic  tremor,  parkinsonism, 
polyneuropathy, and cognitive dysfunctions [2, 21].  
Table 9.   Main X-Linked Ataxias 
Fragile X tremor ataxia syndrome (FXTAS) 
Arts Syndrome 
X-linked adrenoleukodystrophy (X-ALD) 
Congenital ataxias  
Rett syndrome 
Ataxia-Dementia (SCAX4) 
 
III. SPORADIC ATAXIAS  
  This class of ataxias can be divided in (1) degenerative 
and (2) acquired ataxias. Degenerative ataxias include multi-
ple system atrophy (MSA) and idiopathic late-onset cerebel-
lar ataxia (ILOCA) [69]. MSA is a progressive adult-onset 
disease. A cerebellar form (c-MSA) and a parkinsonian form 
(p-MSA) are observed. Patients exhibit dysautonomia.  
  Acquired ataxias are listed in Table 10. The drugs which 
can trigger a cerebellar syndrome are given in Table 11. The 
most common cerebellotoxic agent is alcohol. Chronic con-
sumption  leads  to  cerebellar  atrophy  which  is  most  pro-
nounced in the anterior vermis [95]. The principal neuropa-
thological findings are a loss of Purkinje neurons and a drop 
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contrast, granule cells are relatively resistant to chronic etha-
nol  exposure  [203].  Excitotoxicity  contributes  to  etha-
nol/withdrawal-induced lesions in the cerebellum [129]. Ex-
citatory signaling outweighs  inhibitory transmission. There 
is an excessive glutamate binding to NMDA receptors, fol-
lowed by calcium influx into neuronal cytoplasm. Although 
acute doses of ethanol inhibit the NMDA-mediated toxicity 
of granule cells in culture, chronic administration enhances 
the NMDA receptor activity [91, 92]. Local administration 
of ethanol in cerebellar nuclei in vivo decreases extracellular 
levels of GABA and increases the NMDA-induced produc-
tion of NO [134]. Chronic exposure of Purkinje neurons to 
ethanol increases the AMPA-elicited calcium influx [153]. 
Acute doses of ethanol act also directly on gabaergic path-
ways.  In  particular,  acute  doses  potentiate  the  function  of 
GABA-A receptors, explaining partly the sedative and anti-
anxiety  effects  [119].  Chronic  ethanol  exposure  depresses 
the  expression  of  GABA-A  receptors  alpha1-subunit  and 
increases alpha6-subunit expression, mediating the develop-
ment of tolerance to the motor-impairing effects of ethanol 
[119]. Another mechanism of cerebellar toxicity of ethanol is 
linked  to  the  effects  on  thiamine,  an  essential  cofactor  of 
alpha-ketoglutarate dehydrogenase, pyruvate dehydrogenase 
and transketolase, 3 key-enzymes of energy metabolism and 
lipid synthesis in the brain [95]. The effects of thiamine defi-
ciency on diencephalic lesions in Wernicke encephalopathy 
are well demonstrated [112]. Cerebellum is the site of the 
brain  with  the  highest  turn-over  rate  of  thiamine,  which 
could explain the particular vulnerability of the cerebellum 
to thiamine deficit. Several studies have also underlined the 
relationship between ethanol and oxidative stress. Ethanol-
induced  oxidative  stress  contributes  to  the  observed  apop-
totic  neuron  loss,  with  accumulation  of  4-hydroxynonenal 
(HNE; see section IV), a toxic product of lipid peroxidation 
which  accumulates  in  ethanol-exposed  brain  mitochondria 
and  triggers  a  release  of  apoptosis-inducing  factor  from  
mitochondria in a dose-dependent manner [168].  
  Immune-mediated  ataxias  include:  multiple  sclerosis, 
cerebellar  ataxia  with  anti-glutamic  acid  decarboxylase 
(GAD)  antibodies,  gluten  ataxia,  Miller-Fisher  syndrome, 
systemic  lupus  erythematosus,  Sjögren  syndrome,  Cogan 
syndrome, thyroiditis [7, 15, 75, 180, 190]. In children, tu-
mors  causing  ataxic  syndromes  include  medulloblastomas, 
astrocytomas, and ependymomas [143]. In adults metastatic 
tumors and hemangioblastomas are the most common cere-
bellar neoplasms. Paraneoplastic ataxias often present as  a 
subacute cerebellar syndrome, sometimes mimicking a cere-
bellitis  [104].  Patients  may  present  with  neurologic  symp-
toms before identification of the underlying tumor. Paraneo-
plastic cerebellar degeneration is often mediated by antibod-
ies  usually  generated  against  various  tumor  antigens  (in  
particular  anti-Yo/anti-Hu/anti-Ri/  Anti-mGluR1/Anti-Zic4/ 
anti-CV2 antibodies).  The most commonly associated can-
cers involve the ovary, uterus, breast, lungs, or ataxia may be 
associated with Hodgkin lymphoma. 
IV. TREATMENTS OF CAS 
IV.1. Current Symptomatic Therapy 
  Several  treatments,  mainly  targeting  neurotransmitters, 
have been assessed these last decades. It should be pointed 
out that 4 barriers have hampered meaningful clinical trials 
[219]: the rarity of each cerebellar disorder considered alone, 
the heteregeneous presentation of CAs, the fact that a sub-
stantial degree of neuronal loss has already occurred when 
symptoms appear, and the absence of biomarkers. However, 
some CAs do respond to specific therapies and should not be 
overlooked,  such  as  AVED  which  responds  to  vitamin  E 
supplements [160]. We briefly summarize below the current 
general management of cerebellar disorders.  
Table 10.   Acquired Ataxias 
Stroke (infarction, haemorrhage) 
Toxic-induced (ethanol, heavy metals, solvents, drugs) 
Immune-mediated 
Infectious/parainfectious diseases (abscess, cerebellitis) 
Traumatic 
Context of neoplastic disorder (Primary cancer, metastases,  
chemotherapy, stroke, paraneoplastic) 
Endocrine (hypothyroidism) 
Structural disease (Chiari malformations, agenesis, hypoplasias,  
dysplasias).  
 
Table 11.   Main Drugs which May Trigger Cerebellar Ataxia 
Lithium salts 
Phenytoin 
Valproate 
Amiodarone 
Metronidazole 
Procainamide 
Calcineurin inhibitors 
Mefloquine 
Isoniazid 
 
General Recommandations 
  Speech  rehabilitation  and  regular  physiother-
apy/occupational  therapy  are  recommended  in  CAs.  Most 
patients have some improvements with the use of orthosis, 
sticks, or strollers. Unfortunately, many patients will become 
wheelchair  bound  during  the  course  of  their  illness.  Gas-
trostomy is usually recommended when swallowing difficul-
ties worsen. 
Pharmacotherapy 
  The  principal  drugs  which  have  been  suggested  for 
treatment of nystagmus are gabapentin (a GABA analogue), 
clonazepam, 3, 4-diaminopyridine, baclofen and memantine 
(an  uncompetitive  NMDA  antagonist).  Action  tremor  may 
respond to primidone, beta-adrenergic blocking agents, such 
as  propanolol,  and  to  benzodiazepines  [135].  Appropriate 
medications may be given for associated symptoms such as 
spasticity, parkinsonism, dystonia, bladder dysfunction, and 
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toms  may  improve  with  levodopa  or  dopamine  agonists. 
Spasticity  is  treated  with  baclofen/tinazidine.  Alternatives 
include  benzodiazepines  and  tizanidine.  Dystonia  may  re-
spond  to  diphenhydramide,  benzotropine  mesylate,  or  bi-
periden. Seizures are treated with conventional antiepileptic 
medications.  Myoclonus  may  be  attenuated  with  benzodi-
azepines, high doses of piracetam or sodium valproate. For 
urinary urgencies, the use of spasmolytics or adrenergic a-
receptor blockers is effective. Hypotension may respond to 
increasing salt in the diet or may subside with the use of flu-
drocortisone or midodrine. 
Surgical Therapy 
  High-frequency electrical stimulation (DBS) of the ven-
tral  intermediate  nucleus  (Vim),  or  surgical  lesions 
(thalamotomy), can reduce cerebellar tremor. However, there 
is usually no effect on dysmetria. 
Treatment of Paraneoplastic Cerebellar Ataxia 
  The treatment of the primary cancer should be performed 
as soon as possible in paraneoplastic cerebellar ataxia, hence 
the importance of early detection. Various combinations of 
surgery, chemotherapy and radiotherapy are considered ac-
cording to the neoplasm. Intravenous immunoglobulins and 
plasmaphereses have been used in some cases with variable 
results. The role of intravenous steroids is not established. 
Autosomal Dominant Cerebellar Ataxias (ADCAs) 
  In case of neurodegeneration as observed in SCAs, none 
of the symptomatic therapies mentioned above has stopped 
the  progression  of  the  disease,  although  symptomatic  im-
provements have been reported (Table 11).  Slight benefits 
have been observed using 5-hydroxytryptophan, buspirone or 
tandospirone, sulfamethoxazole/trimethoprim or lamotrigine. 
Acetazolamide may decrease the ataxic symptoms in SCA6. 
Muscle cramps may be disabling, especially in SCA3, and 
may respond to magnesium, quinine, or mexiletine [52, 160, 
233].  
Episodic Ataxias 
  The main treatment for episodic ataxia (EA1) is acetazo-
lamide [81]. 4-aminopyridine, phenytoin and cabamazepine 
are alternatives. Phenytoin and carbamazepine may exacer-
bate symptoms in EA2.  
Recessive Ataxias 
  In  FRDA  patients,  a  monitoring  for  cardiomyopathy  
and  diabetes  yearly  is  important  [188].  Idebenone  (2,  3-
dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone) 
has  been  shown  to  reduce  cardiac  hypertrophy  in  most  
patients, but does not stop progression of  ataxia [46, 139, 
164, 177, 211]. Iron chelators, such as desferoxiamine and 
deferiprone could have beneficial effects [72, 127, 195]. Re-
combinant human erythropoietin (EPO) and peroxisome pro-
liferator  activated receptor gamma  agonists (PPARgamma) 
are  under  investigation  (see  section  IV.2)  [1,  25,  79,  141, 
201]. Beta-blockers at high doses could provide benefits in 
patients with heart involvement.  
  In  AVED,  oral  supplementation  of  vitamin  E  is  the 
treatment of choice to improve the clinical status [186]. ABL 
is also treated with vitamin E. CoQ10 supplementation im-
proves ataxia in case of deficiency of CoQ10. Treatment of 
CTX includes oral administration of chenodeoxycholic acid 
and  statins  such  as  pravastatin  to  inhibit  hydroxyl-
methylglutaryl (HMG)-CoA reductase. Refsum’s disease is 
treated with dietary restriction of phytanic acid.  
Sporadic Ataxias 
  Specific  intoxications  and  endocrine  ataxias  should  be 
treated with specific therapies. Vitamin B1 supplementation 
is recommended in cerebellar degeneration due to alcoholic 
intoxication [95]. Abstinence is mandatory to avoid the pro-
gression of the degeneration. 
  In gluten ataxia, the benefits of a gluten-free diet in the 
treatment of patients with celiac disease are well established 
[75]. The most reliable marker of adherence to a gluten-free 
diet is serological evidence of elimination of circulating anti-
gliadin antibodies [75]. Patients with gluten ataxia in absence 
of enteropathy may improve with intravenous immunoglobu-
lins. Treatment with immunosuppressants should be consid-
ered if strict gluten-free diet has not resulted in improvement 
of ataxia after a year or if the ataxia is rapidly progressive 
[75]. 
  Medications  used  to  slow  the  progression  of  multiple 
sclerosis  include  immune  modulators  such  as  interferons, 
monoclonal  antibodies,  glatiramer  acetate,  mitoxantrone, 
methotrexate,  azathioprine,  cyclophosphamide,  and  natali-
zumab. Steroids may be used to decrease the severity of at-
tacks. It is still unclear whether i.v. (intravenous) immuno-
globulin and plasmapheresis improve patients’ outcomes in 
Miller-Fisher  syndrome  [151].  Steroids  are  also  useful  for 
the  management  of  raised  intra-cranial  pressure  associated 
with cerebellar disorders and for post-infectious cerebellitis 
[236].  
Mitochondrial Disorders 
  High  doses  of  CoQ10  and  N-acetylcysteine  (NAC), 
which was considered as one of the most promising drug, are 
used in maternally inherited mitochondrial diseases, but their 
efficacy is not established. Oxidative stress decreases cellu-
lar bioenergetic capacity, which will generate reactive oxy-
gen species (ROS) [9]. Antioxidants such  as NAC are in-
volved  in  glutathione  regeneration  (Fig.  2).  Cysteine  is 
transported by the alanine-serine-cysteine (ASC) system, but 
NAC does not require any active transport to deliver cysteine 
to the cell [12]. NAC is rapidly hydrolyzed and under the 
consecutive  effects  of  gamma-glutamylcysteine  synthetase 
and  GSH  synthetase,  GSH  is  generated.  This  synthesis  is 
highly limited by the availability of the substrates. Gamma-
glutamylcysteine  synthetase  is  inhibited  by  feedback  from 
GSH (Ki around 1, 5 mM).  Therefore, this enzyme  is not 
operating at its maximal rate under physiological conditions. 
Intracellular  GSH  is  maintained  in  the  thiol  form  by  the 
gluthatione  reductase,  which  requires  NADPH.  GSH  can 
react with non enzymatically with ROS, and GSH peroxidase 
catalyzes the destruction of hydrogen peroxide and hydrop-
eroxides.  From  a  pharmacokinetic  point  of  view,  infused 
NAC rapidly generates disulfides in plasma, which prolongs 
the  existence  of  the  drug  from  a  few  minutes  to  up  to  6 
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ingestion of a dose of 200 mg of NAC. The bioavailability of 
the oral formulation is less than 5 %. This factor contributes 
to the failure of NAC given orally to prevent the raise in 
ROS in neurodegenerative disorders like CAs. 
  Membrane lipid peroxidation results from accumulation 
of ROS. One of the products of lipid peroxidation is HNE 
(Fig. 3), which is associated with inhibition of the activity of 
several types of cellular function and signaling, and exhibits 
cytotoxicity  through  alkylation  [22,  106].  High  levels  of 
HNE  have  been  found  in  the  brain  of  patients  with  Alz-
heimer’s disease (AD). Increased HNE levels have also been 
found in the cerebellum of patients with spinocerebellar de-
generation [235]. HNE-induced neurotoxicity is suppressed 
by Ac-DEVD-CHO, a caspase-3 inhibitor, in rat cerebellar 
granule  neurons,  suggesting  that  HNE-induced  neuronal 
death is attributable to activation of the caspase-3-dependent 
pathway [93]. HNE affects in particular mitochondrial func-
tion, signal transduction, transport function, cytokine produc-
tion and the cytoskeleton [117]. Interestingly, a pre-treatment 
with high concentrations of NAC completely suppresses the 
formation  of  HNE-modified  protein,  mitochondrial  injury 
and neuronal death [8]. This protective effect is due to an 
increase of GSH-HNE conjugation by increased GSH levels 
after treatment with NAC. This highlights  the potential of 
NAC for neurodegenerative disorders. 
IV.2. Current Pharmaceutical Trials  
  Several human trials have been launched these last years, 
especially in FRDA (Table 12). The most promising drugs 
are discussed. 
Idebenone 
  Idebenone is an organic compound of the quinone family 
and promoted commercially as a synthetic analog of CoQ10. 
 
 
 
 
 
 
 
 
 
Fig.  (2).  Mechanism  of  action  of  N-acetylcysteine  (NAC).  ASC,  alanine-serine-cysteine  (ASC)  transport  system;  c-GCS,  c-
glutamylcysteine synthetase; cys, cysteine; glu, glutamine; gly, glycine; GSH, glutathione. Adapted from Arakawa and Ito (2007), [9]. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Potential routes of mitochondrial HNE metabolism. HNE is able to alkylate diverse classes of biological molecules. Balancing 
this toxicity is the metabolism of HNE by multiple phase I and phase II pathways. GS-HNE and GS-HNE acid can dehydrate to form a cyclic 
hemiacetal and lactone, respectively. Adapted from Arakawa and Ito 2007, [9]. 52    Current Neuropharmacology, 2010, Vol. 8, No. 1  Marmolino and Manto 
Idebenone is claimed to have properties similar to CoQ10 in 
terms of antioxidant effects [144]. Idebenone improves defi-
ciencies in electron flow and reduces oxidative stress [120]. 
Parent  idebenone  is  rapidly  metabolized  by  oxidation  and 
side chain shortening to the inactive metabolites QS10, QS8, 
QS6 and QS4 (Fig. 4). Both parent idebenone and the me-
tabolites  may  be  conjugated  to  sulfates  and  glucuronides. 
Phase 1 studies (doses ranging from 150 mg to 1050 mg, 
either as single oral dose or repeated doses) have shown very 
low concentrations of the parent drug, with high inter-subject 
variability  [40].  Cmax  varies  from  1.64  to  23.6  ng/ml  
according  to  studies,  and  tmax  ranges  from  0.87  to  3.37 
hours. Total QS4 is the main metabolic fraction of idebenone 
in  plasma.  The  pharmacokinetics  remain  linear  for  doses 
ranging from 150 mg to 750 mg daily. The bioavailability is 
slightly  increased  when  the  drug  is  given  after  a  fat-rich 
meal. Idebenone is used in Europe in the treatment of vascu-
lar and degenerative diseases of the central nervous system 
[144, 107]. The drug has been used recently in the treatment 
of FRDA [188]. In a one-year  trial on a small number of 
patients, idebenone reduced the rate of deterioration of car-
diac  function,  without  blocking  the  progression  of  ataxia 
[144]. Results of a 3- to 5-years trial suggest that idebenone 
(1) prevents the progression of cardiomyopathy in both pedi-
atric and  adult patients,  and (2) stabilizes  the neurological 
dysfunction in pediatric subjects. EPI-A0001 (Edison Phar-
maceuticals, San Jose, CA, USA), a bioisostere of CoQ10, is 
entering in clinical trials [194]. Penwest Pharmaceuticals has 
just initiated a phase I clinical trial (that will be conducted in 
healthy volunteers) to evaluate its safety and tolerability at 
various doses and to collect pharmacokinetic data. 
Erythropoietin (EPO) 
Clinical trials have started, with encouraging results [25]. In 
one pilot clinical trial, a reduction in oxidative stress markers 
such as urinary 8-hydroxydeoxyguanosine and serum perox-
ides has been observed after 5, 000 IU rhu-EPO administra-
tion for 8 weeks, three times a week. The frataxin increase 
observed in this trial is 27%, with high variability between 
patients (ranging from 15% to 63%). Some non-responders 
Table 12.   Results of Clinical Trials in Spinocerebellar Ataxias (SCAs) Caused by CAG Repeats 
Disease Ref  Treatment  Design of the Trial  Results 
SCA3 [38]  Sulfamethoxazole Trimethoprim  Double-blind, placebo controlled crossover  Improved gait and coordination 
SCA3 [187]  Sulfamethoxazole Trimethoprim  Double-blind, placebo controlled crossover  No effect 
SCA3 [178]  Tetrahydrobiopterin  Double-blind crossover  Improvement on timed tests 
SCA6 [233]  Acetazolamide  Open label  Improvement on Ataxia Rating Scale 
SCA3 [204]  Tandospirone  Open label  Improvement on Ataxia Rating Scale 
From Underwood and Rubinsztein (2008) [219]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Schematic rappresentation of the metabolism of Idebenone. Idebenone is absorbed and can be converted via the oxidative short-
ening or directly being conjugated. The structure of ubiquinone is shown on the upper right corner. Therapies of Cerebellar Ataxias  Current Neuropharmacology, 2010, Vol. 8, No. 1    53 
have been identified. However, considering the commercial 
availability  of  EPO  as  drug  with  assessed  safety,  these  
results are promising. Further longer trials are required. 
Deferiprone (DFP)  
  For systemic iron overload diseases, like hemochromato-
sis, the use of iron chelators (desferal or deferiprone DFP, 
Fig. 5) has an undeniable relevance [24, 170]. However, the 
possible role of iron chelators for the treatment of FRDA and 
other neurodegenerative conditions is still largely controver-
sial [127, 195]. The main point of discussion is the vague-
ness  of  the  molecular  targets  of  the  actual  iron  chelating 
drugs. DFP acts as a siderophore to chelate both cytosolic 
and  mitochondrial  labile  iron.  DFP  redistributes  iron  be-
tween  cellular  compartments  and  to  different  cell  popula-
tions,  including  erythroid  precursors,  to  be  used  for  other 
metabolic purposes, such as the heme biosynthesis. DFP, as 
any other clinically relevant chelator, should be used with 
moderation to avoid overchelation that could affect normal 
cellular iron metabolism and thereby induce iron deficiency 
anemia. The importance of exercising moderation in apply-
ing chelation relates not only to drug dosage but also to drug 
exposure time, as dictated by drug pharmacokinetics. 
Lithium Salts 
  Lithium carbonate, a compound commonly used to treat 
manic  depression,  might  also  provide  symptomatic  relief  
for a group of inherited movement disorders such as SCA1. 
Treatment with lithium salts reduce motor control difficulties 
in the mouse model of SCA1. The drug might slow down 
degenerative  changes  in  the  brain.  Starting  from  this  
important finding, the National Institutes of Health Clinical 
Center (CC) has started a phase I clinical trial (first patient 
recruited in March 2009). It should be pointed out that this 
drug is potentially cerebellotoxic and that a close monitoring 
is  required.  Irreversible  cerebellar  syndromes  have  been  
reported. 
Riluzole 
  Riluzole  preferentially  blocks  tetrodotoxin  (TTX)-
sensitive sodium channels which  are  associated with dam-
aged neurons [197]. This results in a reduction of calcium 
influx and prevents indirectly the  stimulation of glutamate 
receptors. Together with a direct glutamate receptor block-
ade, the deleterious effect of glutamate on motor neurons is 
greatly  reduced.  However,  the  action  of  riluzole  on  gluta-
mate receptors has been controversial, as no binding of the 
molecule has been shown on any known receptor [13, 53, 
231].  A  phase  II  trial  for  multiple  sclerosis  and  inherited 
ataxias is ongoing to  assess efficacy of riluzole (S.Andrea 
Hospital Rome, Italy).  
Valproic Acid 
  Valproic acid (VPA) is primarily used for the treatment 
of epilepsy, bipolar disorder, and major depression. It is also 
prescribed to treat headaches  and schizophrenia. Valproate 
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may  affect  neurotransmitter  GABA  function  (as  a  GABA 
transaminase inhibitor) in the human brain, making it an al-
ternative to lithium salts in treatment of bipolar disorder. In 
addition,  Valproate  may  also  reverse  the  transamination 
process to form more GABA. Hence, VPA acts indirectly as 
a  GABA  agonist.  However,  several  other  mechanisms  of 
action have been proposed [176]. In particular, it might act 
as a histone deacetylase 1(HDAC1) inhibitor. A phase I trial 
has begun in China for SCA3 patients. 
PPAR-γ Agonists 
  PPAR-γ agonists, such as rosiglitazone and pioglitazone, 
are  commonly  used  for  the  treatment  of  diabetes  mellitus 
[171, 172] and represent also a promising therapeutic strat-
egy for other diseases including neurodegenerative disorders 
with an inflammatory component such as Alzheimer’s dis-
ease, Parkinson’s disease, multiple sclerosis, and  amyotro-
phic lateral sclerosis (ALS) [78, 79]. Interestingly, this class 
of molecule has been proposed for mitochondrial diseases, 
because of their ability to increase the response to oxidative 
stress, and to act upon mitochondrial biogenesis [1, 37]. A 
phase  II/III  trial  has  started  at  the  Hôpital  Robert  Debré 
(France) for FRDA. 
V. THERAPIES UNDER DEVELOPMENT  
  New drugs are currently tested in transgenic models of 
CAs. These new strategies are summarized in Table 13. In 
particular, therapeutic strategies which have been successful 
for  Huntington’s  disease  are  being  considered  for  SCAs. 
This is the case for RNAi therapies which aim to inhibit po-
lyglutamine-induced  neurodegeneration.  Prevention  of  pro-
tein misfolding and aggregation by overexpressing chaper-
ones, such as heat-shock protein HSP70 or DNAJ1 are being 
evaluated  [87].  HDAC  inhibitors  can  revert  silent  hetero-
chromatin  to  an  active  chromatin  conformation,  and  thus 
restore the normal function of genes which are silenced in 
these diseases [47, 80, 174]. Today, the precise site of action 
of these inhibitors is still unknown. Moreover, it is of great 
relevance to assess the safety/toxicity of these compounds. 
Nevertheless,  this  innovative  approach  remains  one  of  the 
most interesting options for the treatment of diseases such as 
FRDA or FXTAS in which heterochromatin mediating gene 
silencing occurs. Drugs modulating the cannabinoid recep-
tors and nitric oxide pathways are at a very early stage, and 
require  additional  efforts  to  bring  them  to  the  pre-clinical 
route.  Another  approach  under  development  is  the  use  of 
neurotrophic  factors  promoting  survival  of  Purkinje  cells. 
Two factors play a key-role  in  this function: glial derived 
neurotrophic factor (GDNF) and insulin-like growth factor-1 
(IGF-1), synthetized by  Bergmann glia  and Purkinje  cells/ 
inferior olive, respectively [152]. GDNF promotes both sur-
vival and differentiation of Purkinje neurons, and has shown 
a protective effect in several models of excitoxicity [4, 210]. 
Intra-ventricular administration of GDNF protects the shaker 
mutant rats from loss of Purkinje cells [210]. IGF-1 exerts 
also  neuroprotective  effects.  In  particular,  IGF-1  promotes 
reinnervation  and  functional  recovery  after  inferior  olive 
lesion  [61].  Another  potential  approach  is  based  on  the 
modulation  of  microglial  activation  which  follows  focal 
brain  damage  [225].  Activated  microglial  cells  participate  
in  the  process  of  remote  cell  death  by  producing  pro-
inflammatory  cytokines,  nitric  oxide,  glutamate  and  free 
radicals [23]. Minocycline is a tetracycline derivative which 
reduces  microglial  activation  in  axotomized  precerebellar 
nuclei by modulating the inflammatory response consecutive 
to a cerebellar injury. There is some hope that acting on this 
mechanism may provide benefits for CAs in the future. 
Table 13.   Therapeutical Trials in Cerebellar Ataxias 
FRIEDREICH’S ATAXIA  
Coenzyme Q10 (CoQ10) with E-pilot study 
Idebenone - Phase III 
Mitoquinone (MitoQ) - Phase II 
Erythropoetin (EPO) - pilot, PhaseI/II 
Chelation therapy (Deferiprone) - Phase I/II 
EPI-A0001 (RAID program)-pre-drug 
HDAC inhibitors - pre-drug 
PPARgamma agonists - Phase II/III 
Varenicline - Phase II 
SPORADIC ATAXIAS 
Gluten-free diet—pilot study 
Immunomodulation (IV immunoglobulins, plasmapheresis) -  
pilot study 
 
  Cerebellum is a target of numerous hormones [116, 217]. 
It  is  established  that  hormonal  defects  induce  cerebellar  
lesions  and  that  hormones  interact  with  dendritic  growth, 
spinogenesis  and  synaptogenesis  [216].  Surprisingly,  very 
few experimental studies have attempted to take advantages 
of these effects. The use of hormones for therapy of ataxias 
probably deserves more attention.  
  Transplantation of stem cells is another approach under 
development, but will not be discussed here for a matter of 
clarity. Regarding gene therapy and the use of viral vectors, 
recent advances have contributed to selective and efficient 
gene  transfer  to  Purkinje  cells  in  vivo  [83].  A  promising  
application  of  viral  vectors  is  the  rescue  of  a  deficient  
gene, followed by functional recovery [103]. This strategy 
might become an appealing approach for therapeutic target-
ing  of  disorders  affecting  Purkinje  neurons  in  the  coming 
decades. 
VI.  OVERVIEW  OF  THE  SITES  OF  ACTION  OF 
THERAPIES OF CEREBELLAR ATAXIAS 
  The topic of therapeutics of CAs has been considered as a 
“black box” these last 3 decades. Sets of therapies are being 
evaluated and it is now possible to draw the lines of therapies 
in this category of so-called “untreatable neurological disor-
ders” (Fig. 6): 
-drugs acting at synaptic level 
-drugs targeting the oxidative stress 
-drugs acting on the DNA or RNA  
-drugs aiming to decrease the synthesis of abnormal proteins 
or to increase their clearance.  Therapies of Cerebellar Ataxias  Current Neuropharmacology, 2010, Vol. 8, No. 1    55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Illustration of the sites of action of anti-ataxic drugs. 
Drugs can be gathered in 4 groups according to the mechanism of 
action:  modulation  of  synaptic  activity,  action  against  oxidative 
stress, acting on the DNA/RNA level, and targeting the clearance of 
specific proteins. 
VII. CONCLUSION 
  Our  understanding  of  the  pathogenesis  of  CAs  has  in-
creased dramatically these last 15 years. Unraveling of ge-
netic defects and developments of animal models are reshap-
ing the neuropharmacology of CAs. For the first time, drugs 
under development and ongoing clinical trials aim to restore 
cerebellar function by acting on a deleterious pathway. Sev-
eral avenues of research are still to be explored. One illustra-
tive  example  is the  therapeutics of neuropsychiatric symp-
toms recently characterized in cerebellar patients. As a result 
of the functional heterogeneity of the cerebellar circuitry, it 
is  plausible  that  drugs  under  development  may  selectively 
improve  some  cerebellar  deficits,  whereas  other  therapies 
would improve the full clinical deficits.  
  There is an obvious medical need to develop anti-ataxic 
drugs with proved efficacy. The identification of the molecu-
lar cascades leading to neuronal death in cerebellar circuitry 
will  greatly  help  in  this  endeavor.  Such  knowledge  is  re-
quired  to  develop  potential  therapeutic  agents  in  order  to 
prevent neuronal dysfunction and neurodegeneration. 
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